|
|||||
|
|
Dupilumab for the treatment of asthma |
|
| Authors: | Corrado Pelaia Alessandro Vatrella Luca Gallelli Rosa Terracciano Paolo Navalesi Rosario Maselli |
| Institution: | 1. Department of Medical and Surgical Sciences, University “Magna Gr?cia” of Catanzaro, Catanzaro, Italy;2. Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy;3. Department of Health Science, University “Magna Gr?cia” of Catanzaro, Catanzaro, Italy |
| Abstract: | Introduction: Dupilumab is a fully human IgG4 monoclonal antibody directed against the α subunit of the interleukin (IL)-4 receptor (IL-4Rα). Since the activation of IL-4Rα is utilized by both IL-4 and IL-13 to mediate their pathophysiological effects, dupilumab behaves as a dual antagonist of these two sister cytokines, which blocks IL-4/IL-13-dependent signal transduction. Areas covered: Herein, the authors review the cellular and molecular pathways activated by IL-4 and IL-13, which are relevant to asthma pathobiology. They also review: the mechanism of action of dupilumab, the phase I, II and III studies evaluating the pharmacokinetics as well as the safety, tolerability and clinical efficacy of dupilumab in asthma therapy. Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma. It also may have benefits to comorbidities of asthma including atopic dermatitis, chronic sinusitis and nasal polyposis. |
| Keywords: | Severe asthma IL-4 IL-13 dupilumab |